In addition to the pre-treatment serum CRP/ALB or ALB/CRP ratio, a high post-treatment serum, high-sensitivity CRP (hsCRP)/ALB ratio was shown in a study conducted by Oh et al. [48] to independently predict worse OS and RFS in HCC patients receiving curative surgical resection. This evidence concerns the gene ALB and hepatocellular carcinoma.